Skip to main content
Top
Published in: Annals of Surgical Oncology 3/2017

01-12-2017 | Colorectal Cancer

Comment on: Pathologic Response to Preoperative Chemotherapy in Colorectal Liver Metastases: Fibrosis, Not Necrosis, Predicts Outcome

Authors: Hector H. Li-Chang, MD, FRCPC, David K. Driman, MBChB, FRCPC

Published in: Annals of Surgical Oncology | Special Issue 3/2017

Login to get access

Excerpt

We read with interest the article by Poultsides et al.1 entitled “Pathologic Response to Preoperative Chemotherapy in Colorectal Liver Metastases: Fibrosis, Not Necrosis, Predicts Outcome.” The authors showed that the amount of necrosis in metastases was not associated with improved disease survival in the univariate analysis because it was seen in similar proportions in both treated and untreated tumors. …
Literature
1.
go back to reference Poultsides GA, Bao F, Servais EL, et al. Pathologic response to preoperative chemotherapy in colorectal liver metastases: fibrosis, not necrosis, predicts outcome. Ann Surg Oncol. 2012;19:2797– 804.CrossRefPubMed Poultsides GA, Bao F, Servais EL, et al. Pathologic response to preoperative chemotherapy in colorectal liver metastases: fibrosis, not necrosis, predicts outcome. Ann Surg Oncol. 2012;19:2797– 804.CrossRefPubMed
2.
go back to reference Gruenberger T, Arnold D, Rubbia-Brandt L. Pathologic response to bevacizumab-containing chemotherapy in patients with colorectal liver metastases and its correlation with survival. Surg Oncol. 2012;21:309–15.CrossRefPubMed Gruenberger T, Arnold D, Rubbia-Brandt L. Pathologic response to bevacizumab-containing chemotherapy in patients with colorectal liver metastases and its correlation with survival. Surg Oncol. 2012;21:309–15.CrossRefPubMed
3.
go back to reference Klinger M, Tamandl D, Eipeldauer S, et al. Bevacizumab improves pathological response of colorectal cancer liver metastases treated with XELOX/FOLFOX. Ann Surg Oncol. 2010;17:2059–65.CrossRefPubMed Klinger M, Tamandl D, Eipeldauer S, et al. Bevacizumab improves pathological response of colorectal cancer liver metastases treated with XELOX/FOLFOX. Ann Surg Oncol. 2010;17:2059–65.CrossRefPubMed
4.
go back to reference Rubbia-Brandt L, Giostra E, Brezault C, et al. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neoadjuvant chemotherapy followed by liver surgery. Ann Oncol. 2007;18:299–304.CrossRefPubMed Rubbia-Brandt L, Giostra E, Brezault C, et al. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neoadjuvant chemotherapy followed by liver surgery. Ann Oncol. 2007;18:299–304.CrossRefPubMed
5.
go back to reference Chang HHL, Leeper WR, Chan G, Quan D, Driman DK. Infarct-like necrosis: a distinct form of necrosis seen in colorectal carcinoma liver metastases treated with perioperative chemotherapy. Am J Surg Pathol. 2012;36:570–6.CrossRefPubMed Chang HHL, Leeper WR, Chan G, Quan D, Driman DK. Infarct-like necrosis: a distinct form of necrosis seen in colorectal carcinoma liver metastases treated with perioperative chemotherapy. Am J Surg Pathol. 2012;36:570–6.CrossRefPubMed
Metadata
Title
Comment on: Pathologic Response to Preoperative Chemotherapy in Colorectal Liver Metastases: Fibrosis, Not Necrosis, Predicts Outcome
Authors
Hector H. Li-Chang, MD, FRCPC
David K. Driman, MBChB, FRCPC
Publication date
01-12-2017
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue Special Issue 3/2017
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-017-6198-3

Other articles of this Special Issue 3/2017

Annals of Surgical Oncology 3/2017 Go to the issue